• Je něco špatně v tomto záznamu ?

Experimental and Established Oximes as Pretreatment before Acute Exposure to Azinphos-Methyl

DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu

. 2021 ; 22 (6) : . [pub] 20210317

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019035

Poisoning with organophosphorus compounds (OPCs) represents an ongoing threat to civilians and rescue personal. We have previously shown that oximes, when administered prophylactically before exposure to the OPC paraoxon, are able to protect from its toxic effects. In the present study, we have assessed to what degree experimental (K-27; K-48; K-53; K-74; K-75) or established oximes (pralidoxime, obidoxime), when given as pretreatment at an equitoxic dosage of 25% of LD01, are able to reduce mortality induced by the OPC azinphos-methyl. Their efficacy was compared with that of pyridostigmine, the only FDA-approved substance for such prophylaxis. Efficacy was quantified in rats by Cox analysis, calculating the relative risk of death (RR), with RR=1 for the reference group given only azinphos-methyl, but no prophylaxis. All tested compounds significantly (p ≤ 0.05) reduced azinphos-methyl-induced mortality. In addition, the efficacy of all tested experimental and established oximes except K-53 was significantly superior to the FDA-approved compound pyridostigmine. Best protection was observed for the oximes K-48 (RR = 0.20), K-27 (RR = 0.23), and obidoxime (RR = 0.21), which were significantly more efficacious than pralidoxime and pyridostigmine. The second-best group of prophylactic compounds consisted of K-74 (RR = 0.26), K-75 (RR = 0.35) and pralidoxime (RR = 0.37), which were significantly more efficacious than pyridostigmine. Pretreatment with K-53 (RR = 0.37) and pyridostigmine (RR = 0.52) was the least efficacious. Our present data, together with previous results on other OPCs, indicate that the experimental oximes K-27 and K-48 are very promising pretreatment compounds. When penetration into the brain is undesirable, obidoxime is the most efficacious prophylactic agent already approved for clinical use.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019035
003      
CZ-PrNML
005      
20210830100610.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22063072 $2 doi
035    __
$a (PubMed)33802843
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lorke, Dietrich E $u Department of Anatomy and Cellular Biology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates $u Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi P.O. Box 127788, United Arab Emirates
245    10
$a Experimental and Established Oximes as Pretreatment before Acute Exposure to Azinphos-Methyl / $c DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu
520    9_
$a Poisoning with organophosphorus compounds (OPCs) represents an ongoing threat to civilians and rescue personal. We have previously shown that oximes, when administered prophylactically before exposure to the OPC paraoxon, are able to protect from its toxic effects. In the present study, we have assessed to what degree experimental (K-27; K-48; K-53; K-74; K-75) or established oximes (pralidoxime, obidoxime), when given as pretreatment at an equitoxic dosage of 25% of LD01, are able to reduce mortality induced by the OPC azinphos-methyl. Their efficacy was compared with that of pyridostigmine, the only FDA-approved substance for such prophylaxis. Efficacy was quantified in rats by Cox analysis, calculating the relative risk of death (RR), with RR=1 for the reference group given only azinphos-methyl, but no prophylaxis. All tested compounds significantly (p ≤ 0.05) reduced azinphos-methyl-induced mortality. In addition, the efficacy of all tested experimental and established oximes except K-53 was significantly superior to the FDA-approved compound pyridostigmine. Best protection was observed for the oximes K-48 (RR = 0.20), K-27 (RR = 0.23), and obidoxime (RR = 0.21), which were significantly more efficacious than pralidoxime and pyridostigmine. The second-best group of prophylactic compounds consisted of K-74 (RR = 0.26), K-75 (RR = 0.35) and pralidoxime (RR = 0.37), which were significantly more efficacious than pyridostigmine. Pretreatment with K-53 (RR = 0.37) and pyridostigmine (RR = 0.52) was the least efficacious. Our present data, together with previous results on other OPCs, indicate that the experimental oximes K-27 and K-48 are very promising pretreatment compounds. When penetration into the brain is undesirable, obidoxime is the most efficacious prophylactic agent already approved for clinical use.
650    _2
$a zvířata $7 D000818
650    _2
$a azinfos-methyl $x chemie $x toxicita $7 D001387
650    _2
$a cholinesterasové inhibitory $x farmakologie $7 D002800
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a molekulová hmotnost $7 D008970
650    _2
$a organofosforové sloučeniny $x chemie $x toxicita $7 D009943
650    _2
$a oximy $x farmakologie $7 D010091
650    _2
$a pesticidy $x chemie $x toxicita $7 D010575
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a potkani Wistar $7 D017208
650    _2
$a riziko $7 D012306
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nurulain, Syed M $u Bio Science Department, COMSATS Institute of Information Technology, Bio Sciences Block, CUI, Park Road, Tarlai Kalan, Islamabad 45550, Pakistan
700    1_
$a Hasan, Mohamed Y $u Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, UAE University, Al Ain P.O. Box 15551, United Arab Emirates
700    1_
$a Kuča, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62/26, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Petroianu, Georg A $u Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33802843 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100610 $b ABA008
999    __
$a ok $b bmc $g 1689960 $s 1139481
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 6 $e 20210317 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace